Jazz Pharmaceuticals
↗Dublin, Ireland
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, founded in 2003. The company focuses on developing innovative medicines for people with serious diseases, particularly in oncology and neuroscience therapeutic areas. Jazz has transformed from a narcolepsy-focused company (built on the Xyrem franchise) into a diversified specialty pharma leader through strategic acquisitions including GW Pharmaceuticals (2021, $7.2B), Chimerix (2024), and multiple other M&A transactions. The company employs approximately 2,800-3,400 people across six continents with R&D, manufacturing, and commercial operations in North America, Europe, and Asia.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharma, Oncology, Neuroscience
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$4.0B-$4.5B
Founded:2003
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:JAZZ
Market Cap:$11.7B
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial (Epidiolex, Xywav) and Phase 3 (Zanidatamab)
Modalities:Small molecule, Bispecific antibody, Monoclonal antibody, Cannabinoid, Enzyme inhibitor
Active Trials:8
Trial Phases:Phase 1: 2 | Phase 2: 4 | Phase 3: 2
FDA Approvals:3
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Jazz Pharmaceuticals Inc (USA), Jazz Pharmaceuticals UK Ltd, Jazz Pharmaceuticals Ireland Limited, GW Pharmaceuticals Ltd (UK), Gentium Srl (Italy), Celator Pharmaceuticals Inc (USA), Chimerix Inc (USA), Cavion Inc (USA)
Key Partnerships:BeOne Medicines (Zanidatamab collaboration), University of Texas MD Anderson Cancer Center (JZP351 trials), Redx Pharma (KRAS inhibitor acquisition agreement - $10M upfront, up to $870M milestones), Various university medical centers for clinical research
COMPETITION
Position:Challenger/Leader in niche areas
Competitors:AstraZeneca (HER2-targeted therapies, oncology), Pfizer (broad oncology portfolio), Johnson & Johnson (oncology and neurology), Novartis (oncology, rare disease), ImmunoGen (biologics), Pharmacyclics (oncology), Biogen (neuroscience), Multiple generic manufacturers (oxybate products)
LEADERSHIP
Key Executives:
Renée Gala - President and Chief Executive Officer
Bruce C. Cozadd - Chairman of the Board
Philip L. Johnson - Executive Vice President and Chief Financial Officer
Robert Iannone, M.D., M.S.C.E. - Executive Vice President, Global Head of R&D, Chief Medical Officer
Samantha Pearce - Chief Commercial Officer
Neena Patil - Executive Vice President and Chief Legal Officer
Scientific Founders:Bruce C. Cozadd (founder, March 5, 2003)
LINKS
Website:jazzpharma.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jazz Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jazz Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.